Welcome to our dedicated page for Kyverna Therapeutics SEC filings (Ticker: KYTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kyverna Therapeutics, Inc. (Nasdaq: KYTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Kyverna is a clinical-stage biopharmaceutical company focused on CD19-targeting CAR T-cell therapies for autoimmune diseases, and its filings offer detailed information on clinical progress, financing arrangements, and governance matters.
Investors can review Form 8-K current reports in which Kyverna describes material events such as positive topline data from the KYSA-8 registrational Phase 2 trial of mivocabtagene autoleucel (miv-cel, KYV-101) in stiff person syndrome, interim Phase 2 data from the KYSA-6 registrational trial in generalized myasthenia gravis, and guidance on anticipated regulatory steps like a planned Biologics License Application for SPS. Other 8-K filings outline a loan and security agreement with Oxford Finance LLC, the terms of an underwritten public offering of common stock under an effective Form S-3 shelf registration statement, and leadership changes including the appointment of an Executive Chairperson of the Board.
Through this page, users can also locate references to Kyverna’s status as an emerging growth company, details on its Nasdaq-listed common stock under the ticker KYTX, and exhibits such as underwriting agreements, legal opinions, and investor presentations. Stock Titan’s interface surfaces these filings as they are made available on EDGAR and pairs them with AI-powered summaries that highlight key points, helping readers quickly understand the significance of each document without parsing all of the legal language.
For those researching KYTX, this filings hub is a central resource for tracking Kyverna’s reported clinical milestones, financial obligations, equity offerings, and board-level decisions as disclosed in its SEC submissions.
Kyverna Therapeutics, Inc. director Emany Sravan Kumar filed an initial ownership report on Form 3. The filing identifies Kumar as a director of Kyverna but does not list any transactions or report any share purchases, sales, acquisitions, or dispositions at this time.
Kyverna Therapeutics appointed two new independent directors as it refreshes its board. Andrew Miller, Ph.D., founder and former R&D president of Karuna Therapeutics, joins as a Class III director and member of the Audit and Science and Technology Committees. He will receive annual cash retainers for board and committee service and initial equity awards sized at $262,000 in stock options and $87,500 in restricted stock units, subject to service-based vesting and full vesting on a Change in Control.
Sravan Emany, CFO of Beam Therapeutics and former CFO/COO of Ironwood Pharmaceuticals, joins as a Class I director, Chair of the Audit Committee and member of the Nominating and Corporate Governance Committee, with similar cash and equity compensation levels and change-in-control vesting. Director Daniel Spiegelman resigned effective February 24, 2026, and the company states his resignation was not due to any disagreement with operations, policies or practices.
Kyverna Therapeutics, Inc. investors led by Northpond entities and Michael P. Rubin report their beneficial ownership in an amended Schedule 13G as of December 31, 2025. Michael P. Rubin is shown with beneficial ownership of 3,466,826 shares of common stock, representing 6.1% of the class.
The filing lists 2,805,426 shares (4.9%) held by Northpond Ventures III, LP, 450,000 shares (0.8%) held by Northpond Ventures, LP, and 211,400 shares (0.4%) held by NVP Listed, LLC, with shared voting and dispositive power over these positions. The percentages are based on 43,796,170 shares outstanding as of October 31, 2025 plus 13,333,333 shares issued in a December 18, 2025 public offering. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Kyverna.
Bain Capital Life Sciences Opportunities III, LP reported a significant ownership stake in Kyverna Therapeutics, Inc. common stock. As of the close of business on December 31, 2025, the fund beneficially owned 3,110,000 shares, representing approximately 5.4% of Kyverna’s outstanding common stock.
The filing states that these shares are held with shared voting and dispositive power through a chain of Bain Capital Life Sciences entities organized in Delaware. The ownership percentage is based on 57,127,420 shares outstanding reported by Kyverna in a prospectus supplement filed on December 18, 2025.
The reporting person certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Kyverna, but rather as a passive investment under the applicable beneficial ownership rules.
Kyverna Therapeutics, Inc. executive Mayobanex Pujols, the company’s Chief Technology Officer, filed an initial ownership report on Form 3. The filing states that no securities of Kyverna Therapeutics, Inc. are beneficially owned by the reporting person.
Kyverna Therapeutics’ Chief Technology Officer, Mayobanex Pujols, received a grant of stock options for 300,000 shares of common stock on February 9, 2026, with an exercise price of $8.08 per share. These options were acquired as a compensatory award and are held directly.
According to the vesting terms, one-fourth of the option shares vest on February 9, 2027. The remaining shares vest in 1/48th increments each month thereafter, contingent on Pujols’ continuous service with Kyverna through each vesting date. After this grant, he beneficially owns 300,000 derivative securities in the form of these options.
Kyverna Therapeutics, Inc. received an updated ownership report showing that funds affiliated with Westlake BioPartners and Dr. Beth C. Seidenberg beneficially own a significant minority stake in the company’s common stock.
Westlake BioPartners Fund I, L.P. reports beneficial ownership of 3,787,940 shares of Kyverna common stock, representing 6.3% of the class. Westlake BioPartners Opportunity Fund I, L.P. reports 869,317 shares, or 1.5% of the class. In total, Dr. Seidenberg is reported as beneficially owning 4,657,257 shares, or 7.8% of Kyverna’s common stock as of the December 31, 2025 event date.
The filing explains that these shares are held through Westlake limited partnerships, with their respective general partners and Dr. Seidenberg “may be deemed” to have sole voting and dispositive power, while all reporting persons disclaim beneficial ownership beyond their pecuniary interest. The amendment also notes that Dr. Sean E. Harper is no longer a managing director of the general partners and is therefore removed as a reporting person.
Kyverna Therapeutics, Inc. reported a leadership transition and a change to its inducement equity plan. Karen Walker notified the company on January 29, 2026 that she will retire and step down as Chief Technology Officer, effective February 9, 2026. The company noted that her resignation is not due to any disagreement regarding operations, policies, or practices.
On the same date, the board’s Compensation Committee amended and restated the 2024 Inducement Equity Incentive Plan to increase the shares of common stock available for grant by 1,000,000, bringing the aggregate to 5,000,000 shares. This change was adopted without stockholder approval under Nasdaq Listing Rule 5635(c)(4) and maintains the plan’s focus on equity awards used as material inducements for new or rehired employees. The company also announced the appointment of Mayo Pujols as Chief Technology Officer, effective February 9, 2026.
Kyverna Therapeutics Executive Chairperson Shaw Christi reported new equity awards from the company. On January 12, 2026, Shaw Christi received 30,000 shares of common stock as a restricted stock unit award, which vests in four equal annual installments starting January 12, 2027, subject to continued service.
She also received 24,301 performance restricted stock units that vest only if Kyverna’s common stock reaches specified share price targets. In addition, she was granted a stock option for 185,000 shares of common stock at an exercise price of $8.23 per share, with one quarter vesting on January 12, 2027 and the remainder vesting monthly thereafter, conditioned on continued service. Following these awards, she beneficially owned 70,935 shares of common stock and 185,000 stock options directly.
Kyverna Therapeutics appointed Christi Shaw as Executive Chairperson of its Board, effective January 12, 2026. She will replace Ian Clark as Chairperson, who will continue to serve as a director. Shaw will be employed on an at-will basis with an initial annual salary of $400,000.
As part of her compensation, Shaw will receive an option to purchase 185,000 shares of common stock and 30,000 restricted stock units, each vesting over four years, along with performance RSUs equal to $200,000 divided by the grant-date fair market value, which vest upon achieving specified stock price targets. If a change in control occurs during her employment, all of her unvested equity awards will fully vest, with performance targets deemed achieved at the target level.
The company also furnished a press release providing a corporate update, strategic priorities for 2026, and preliminary unaudited financial information for the year ended December 31, 2025, which may change upon completion of year-end procedures.